Nifty
:
16266.15
Sensex
:
54326.39
456.75 (2.89%)
1534.16 (2.91%)
Nifty
Sensex
:
:
16266.15
54326.39
456.75 (2.89%)
1534.16 (2.91%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
41/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
407.50
20-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  399.00
  •  409.00
  •  397.10
  •  392.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  555699
  •  2248.27
  •  690.95
  •  386.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,495.53
  • 11.27
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 15,043.80
  • 0.61%
  • 1.29

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 1.23%
  • 15.88%
  • FII
  • DII
  • Others
  • 24.12%
  • 10.35%
  • 1.77%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.53
  • 3.81
  • 3.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.30
  • 0.46
  • 5.62

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.74
  • -2.64
  • 1.60

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.81
  • 15.15
  • 14.39

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.34
  • 2.47
  • 1.91

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.85
  • 9.38
  • 8.23

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Net Sales
3,173.41
2,786.76
13.87%
3,147.45
2,952.48
6.60%
2,964.89
2,344.79
26.45%
2,859.90
2,767.49
3.34%
Expenses
2,480.26
2,256.69
9.91%
2,557.28
2,399.67
6.57%
2,391.32
1,866.72
28.10%
2,336.47
2,301.80
1.51%
EBITDA
693.15
530.07
30.77%
590.17
552.81
6.76%
573.58
478.07
19.98%
523.43
465.69
12.40%
EBIDTM
21.84%
19.02%
18.75%
18.72%
19.35%
20.39%
18.30%
16.83%
Other Income
13.89
15.09
-7.95%
-13.07
-31.88
-
58.65
58.51
0.24%
8.49
44.14
-80.77%
Interest
66.70
95.41
-30.09%
68.95
80.63
-14.49%
75.60
93.74
-19.35%
83.33
98.47
-15.38%
Depreciation
118.93
115.20
3.24%
123.19
104.07
18.37%
113.07
113.22
-0.13%
111.07
126.28
-12.04%
PBT
343.04
347.97
-1.42%
384.96
339.38
13.43%
443.55
357.61
24.03%
337.51
317.96
6.15%
Tax
103.29
99.79
3.51%
110.16
105.38
4.54%
137.03
103.57
32.31%
103.65
97.65
6.14%
PAT
239.75
248.18
-3.40%
274.81
233.99
17.45%
306.53
254.04
20.66%
233.87
220.31
6.15%
PATM
7.55%
8.91%
8.73%
7.93%
10.34%
10.83%
8.18%
7.96%
EPS
7.86
8.79
-10.58%
9.13
8.29
10.13%
10.86
9.00
20.67%
8.29
7.81
6.15%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
12,145.65
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
4,020.64
Net Sales Growth
11.93%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
23.59%
 
Cost Of Goods Sold
4,292.78
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
1,291.00
Gross Profit
7,852.87
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
2,729.65
GP Margin
64.66%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
67.89%
Total Expenditure
9,765.33
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
3,306.28
Power & Fuel Cost
-
164.67
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
0.00
% Of Sales
-
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
0%
Employee Cost
-
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
628.89
% Of Sales
-
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
15.64%
Manufacturing Exp.
-
804.63
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
54.40
% Of Sales
-
7.35%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
1.35%
General & Admin Exp.
-
825.28
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
678.94
1,331.99
% Of Sales
-
7.54%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
33.13%
Selling & Distn. Exp.
-
979.64
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
0.00
% Of Sales
-
8.95%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
0%
Miscellaneous Exp.
-
121.44
47.19
33.29
314.55
88.52
38.82
38.48
228.40
33.61
0.00
% Of Sales
-
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
0%
EBITDA
2,380.33
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
714.36
EBITDA Margin
19.60%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
17.77%
Other Income
67.96
50.22
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
18.17
Interest
294.58
353.11
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
146.57
Depreciation
466.26
443.55
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
97.88
PBT
1,509.06
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
488.09
Tax
454.13
412.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
23.78
Tax Rate
30.09%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
4.87%
PAT
1,054.96
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
460.35
PAT before Minority Interest
1,019.97
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
464.31
Minority Interest
-34.99
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
-3.96
PAT Margin
8.69%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
11.45%
PAT Growth
10.29%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
34.69%
 
EPS
37.38
34.37
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97
16.31

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
2,401.63
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
27.05
Total Reserves
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
2,374.58
Non-Current Liabilities
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
1,137.64
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
1,312.47
Unsecured Loans
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
14.58
Current Liabilities
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
1,901.74
Trade Payables
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
788.83
Other Current Liabilities
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
414.83
Short Term Borrowings
513.01
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
687.46
Short Term Provisions
564.45
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
10.63
Total Liabilities
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
5,466.01
Net Block
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
2,237.30
Gross Block
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
2,650.96
Accumulated Depreciation
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
413.66
Non Current Assets
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
2,518.85
Capital Work in Progress
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
248.33
Non Current Investment
24.63
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
0.00
Long Term Loans & Adv.
146.29
123.97
94.36
119.78
98.94
69.99
468.16
33.39
36.52
0.00
Other Non Current Assets
27.89
26.49
15.80
0.56
0.13
0.16
0.27
20.33
22.00
33.23
Current Assets
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
2,947.15
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
787.67
Sundry Debtors
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
1,243.61
Cash & Bank
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
321.92
Other Current Assets
1,371.53
603.30
765.22
810.78
1,273.61
986.77
774.38
872.81
635.91
593.95
Short Term Loans & Adv.
672.06
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
518.90
Net Current Assets
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
1,045.41
Total Assets
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91
5,466.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
804.39
PBT
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
488.09
Adjustment
644.82
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
484.05
Changes in Working Capital
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
-34.79
Cash after chg. in Working capital
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
937.35
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
-132.96
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
-277.79
Net Fixed Assets
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
-54.88
Net Investments
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
-42.02
Others
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
-180.89
Cash from Financing Activity
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
-361.39
Net Cash Inflow / Outflow
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
165.21
Opening Cash & Equivalents
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
194.87
Closing Cash & Equivalent
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
249.60
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
88.77
ROA
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
9.01%
ROE
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
20.92%
ROCE
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
14.44%
Fixed Asset Turnover
1.29
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
1.60
Receivable days
83.06
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
107.78
Inventory Days
73.58
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
72.38
Payable days
219.98
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
108.47
Cash Conversion Cycle
-63.33
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
71.69
Total Debt/Equity
0.67
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
0.93
Interest Cover
4.92
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62
4.33

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Glenmark Pharmaceuticals’ arm recalls over 32,000 bottles of Zonisamide capsules
    16th May 2022, 12:36 PM

    As per US Food and Drug Administration (USFDA), the US firm, a unit of Mumbai-based Glenmark Pharmaceuticals, is recalling the affected lot due to ‘CGMP deviations’

    Read More
  • Glenmark Pharma’s arm gets tentative nod for Calcipotriene and Betamethasone Dipropionate Foam
    9th May 2022, 09:37 AM

    Calcipotriene and Betamethasone Dipropionate Foam, 0.005%-0.064%, is the generic version of Enstilar Foam, 0.005%-0.064%, of Leo Pharma AS

    Read More
  • Glenmark Pharmaceuticals wins ‘India Pharma Innovation of the Year’ award
    27th Apr 2022, 17:30 PM

    The award recognizes Glenmark’s multiple patents and innovations in its core therapy areas of Dermatology, Respiratory and Oncology, over the last three years

    Read More
  • Glenmark Pharma launches 'Teneligliptin + Pioglitazone' fixed-dose combination drug
    25th Apr 2022, 09:14 AM

    This fixed dose combination will be useful for patients who require treatment with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control reducing Insulin Resistance

    Read More
  • Glenmark Pharma’s arm gets DCGI nod to conduct Phase 1 Clinical Trial of Novel Molecule GRC 54276
    11th Apr 2022, 09:11 AM

    The study will evaluate the safety and tolerability of GRC 54276 as a monotherapy, and also in combination with checkpoint inhibitors in patients with advanced solid tumors and Hodgkin’s lymphoma

    Read More
  • Glenmark Pharmaceuticals raises sustainability-linked loan of $228 million
    23rd Mar 2022, 10:45 AM

    The five-year loan is priced at 175 basis points over the London interbank offered rate

    Read More
  • Glenmark Pharma’s arm receives USFDA’s final approval for Lacosamide Tablets
    21st Mar 2022, 09:16 AM

    The company plans to launch the product immediately

    Read More
  • Glenmark’s arm inks agreement to commercialize ‘Pulmicort Respules’ in Columbia
    14th Feb 2022, 15:04 PM

    The company will be responsible for commercialization of Pulmicort Respules in the Colombian market

    Read More
  • Glenmark Pharmaceuticals reports marginal fall in Q3 consolidated net profit
    12th Feb 2022, 10:04 AM

    Total consolidated income of the company increased by 13.75% at Rs 3187.31 crore for Q3FY22

    Read More
  • Glenmark Pharma - Quarterly Results
    11th Feb 2022, 22:40 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.